Resource Summary Report

Generated by NIF on Sep 15, 2026

IGF2BP2/IMP2 Antibody, RIP-grade

RRID:AB_1570641
Type: Antibody

Proper Citation

MBL International Cat# RN008P, RRID:AB_1570641

Antibody Information

URL: http://antibodyregistry.org/AB_1570641

Proper Citation: MBL International Cat# RN008P, RRID:AB_1570641

Target Antigen: IGF2BP2/IMP2 RIP-grade

Host Organism: rabbit

Clonality: unknown

Comments: manufacturer recommendations: Radioimmunoassay; Western Blot; Immunoprecipitation; RIP, WB, IPP

Antibody Name: IGF2BP2/IMP2 Antibody, RIP-grade

Description: This unknown targets IGF2BP2/IMP2 RIP-grade

Target Organism: human

Antibody ID: AB_1570641

Vendor: MBL International

Catalog Number: RN008P

Record Creation Time: 20231110T063034+0000

Record Last Update: 20260901T041922+0000

Ratings and Alerts

- ENCODE PROJECT External validation for lot: 1 is available under ENCODE ID: ENCAB000BFQ - ENCODE

https://www.encodeproject.org/antibodies/ENCAB000BFQ

No alerts have been found for IGF2BP2/IMP2 Antibody, RIP-grade.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Her HL, et al. (2026) Comprehensive RNA-binding protein analyses and deep learning uncover genetic constraints and disease associations in protein-RNA interfaces. Cell systems, 17(6), 101588.

Cheng Y, et al. (2023) Decoding m6A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance. Cell stem cell, 30(1), 69.

Yin R, et al. (2022) Differential m6A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell function. Cell stem cell, 29(1), 149.

Han W, et al. (2022) Targeting HOTAIRM1 ameliorates glioblastoma by disrupting mitochondrial oxidative phosphorylation and serine metabolism. iScience, 25(8), 104823.

Ladha FA, et al. (2021) Actinin BioID reveals sarcomere crosstalk with oxidative metabolism through interactions with IGF2BP2. Cell reports, 36(6), 109512.

Hanniford D, et al. (2020) Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer cell, 37(1), 55.